(Q37968143)

26 August 2017

Biologics-based therapy for the treatment of rheumatoid arthritis (English)

1 reference

26 August 2017

1 reference

D L Scott

1

1 reference

PubMed ID

22166850

26 August 2017

language of work or name

English

0 references

publication date

14 December 2011

1 reference

26 August 2017

14

1 reference

Clinical Pharmacology & Therapeutics

inferred from page(s)

published in

1 reference

26 August 2017

91

1 reference

26 August 2017

1

1 reference

26 August 2017

30-43

1 reference

https://scigraph.springernature.com/pub.10.1038/clpt.2011.278

26 August 2017

0 references

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Prevalence and incidence of rheumatoid arthritis in southern Sweden 2008 and their relation to prescribed biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Incidence of rheumatoid arthritis from 1995 to 2001: impact of ascertainment from multiple sources.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

The Simplified Disease Activity Index and Clinical Disease Activity Index to monitor patients in standard clinical care

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Rheumatoid arthritis: assessing disease activity and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Radiographic measures to assess patients with rheumatoid arthritis: advantages and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Early rheumatoid arthritis: a review of MRI and sonographic findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Patient-driven outcomes in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Effectiveness of nonpharmacological and nonsurgical interventions for patients with rheumatoid arthritis: an overview of systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Cytokine pathways and joint inflammation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Anti-TNF therapy from the bench to the clinic: a paradigm of translational research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Clinical value of blocking IL-6 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Abatacept therapy and safety management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Comparative overview of safety of the biologics in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with specia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Perioperative management of immunosuppression in rheumatic diseases--what to do?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Are clinical trials in rheumatoid arthritis generalizable to routine practice? A re-evaluation of trial entry criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

When to initiate and discontinue biologic treatments for rheumatoid arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Management of rheumatoid arthritis: summary of NICE guidance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

Modelling the cost effectiveness of TNF- antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

7 January 2021

The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

7 January 2021

Development of anti-TNF therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

7 January 2021

The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

7 January 2021

The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

7 January 2021

Functional analysis of rheumatoid factor-producing B cells from the synovial fluid of rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

7 January 2021

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

7 January 2021

Utility-based outcomes made easy: The number needed per quality-adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

7 January 2021

Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

7 January 2021

Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.278

7 January 2021

Identifiers

DOI

10.1038/CLPT.2011.278

1 reference

PubMed ID

22166850

Dimensions Publication ID

26 August 2017

0 references

1 reference

PubMed ID

22166850